• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ: MLTX )

    45.76 -1.00 (-2.13%)
    Streaming Delayed Price Updated: 9:58 AM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

    < Previous 1 2 3 4 5 Next >
    MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
    From MoonLake Immunotherapeutics AG
    Via GlobeNewswire
    MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
    From MoonLake Immunotherapeutics AG
    Via GlobeNewswire
    MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
    MLTX stock results show that MoonLake missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
    From Komodo Health
    Via Business Wire
    Expert Ratings for MoonLake
    Via Benzinga
    Recap: MoonLake Q3 Earnings
    Via Benzinga
    Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
    The company tested its psoriatic arthritis drug over 24 weeks against Humira. 
    Via Investor's Business Daily
    16 Analysts Have This to Say About MoonLake
    Via Benzinga
    Where MoonLake Stands With Analysts
    Via Benzinga
    Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
    Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors. 
    Via Benzinga
    MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
    From MoonLake Immunotherapeutics AG
    Via GlobeNewswire
    MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
    From MoonLake Immunotherapeutics AG
    Via GlobeNewswire
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
    From MoonLake Immunotherapeutics AG
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Why Former Highflier MoonLake Plummeted 29% After A Recent Run
    The company tested its drug over 12 weeks in 207 patients. All but one regimen led to statistically significant improvements. 
    Via Investor's Business Daily
    Dow Turns Lower; EchoStar Shares Plunge
    U.S. stocks turned lower toward the end of trading, with the Dow Jones falling around 50 points on Monday The Dow traded down 0.16% to 34,007.81 while the NASDAQ fell 0.08% to 13,467.42. The S&P 500... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
    U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Is Arthritis-Focused MoonLake Immunotherapeutics Stock Trading Lower Today?
    Sunday, MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with  
    Via Benzinga
    TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday
    U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    US Stocks Rise; Nasdaq Gains 50 Points
    U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday Following the market opening Monday, the Dow traded up 0.21% to 34,133.62 while the NASDAQ rose... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
    From MoonLake Immunotherapeutics AG
    Via GlobeNewswire
    MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst
    MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week... 
    Via Benzinga
    Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
    U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
    Via Benzinga
    Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
    MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.